Trial Profile
A retrospective study to evaluate the efficacy and safety of combination of Bendamustine+ Rituximab in patients with relapsed or refractory Diffuse-large-B-cell-lymphoma.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Nov 2015
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Rituximab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 29 Nov 2015 New trial record